Experienced in Febrile Neutropenia

Jeffrey Yachnin

Huddinge, AB, SE 
Experienced in Febrile Neutropenia
Huddinge, AB, SE 
OverviewLocationsClinical Research

Overview

Jeffrey Yachnin practices in Huddinge, Sweden. Mr. Yachnin is rated as an Experienced expert by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Synovial Sarcoma, Prostate Cancer, Pancreatic Cancer, and Necrosis.

His clinical research consists of co-authoring 29 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Febrile Neutropenia.

Gender
Male

Locations

Huddinge, AB, Sweden
Other Locations
Stockholm, AB, Sweden
Solna, AB, Sweden
Eskilstuna, D, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class
MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class
Enrollment Status: Completed
Publish Date: September 09, 2025
Intervention Type: Drug
Study Phase: Phase 1
Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors
Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drugs: GSK3901961, GSK3845097, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A First-in-human, Multicenter, Open-label, Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of Intravenously Administered ATOR-1015
A First-in-human, Multicenter, Open-label, Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of Intravenously Administered ATOR-1015
Enrollment Status: Completed
Publish Date: August 18, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase Ia/Ib, First-in-human, Open Label, Multicentre, Dose-escalation and Dose-expansion Study of a Novel NanoZolid®-Docetaxel Depot Formulation (NZ-DTX Depot) Given as an Intra-tumoural Injection in Patients With Advanced Solid Tumours
A Phase Ia/Ib, First-in-human, Open Label, Multicentre, Dose-escalation and Dose-expansion Study of a Novel NanoZolid®-Docetaxel Depot Formulation (NZ-DTX Depot) Given as an Intra-tumoural Injection in Patients With Advanced Solid Tumours
Enrollment Status: Terminated
Publish Date: December 30, 2021
Intervention Type: Drug
Study Phase: Phase 1
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
Enrollment Status: Completed
Publish Date: December 29, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A First-in-human, Multicenter, Open-label, Multiple Ascending Dose Phase I Study in Patients With Advanced Solid Tumors to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intratumorally or Intravenously Administered ADC-1013
A First-in-human, Multicenter, Open-label, Multiple Ascending Dose Phase I Study in Patients With Advanced Solid Tumors to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intratumorally or Intravenously Administered ADC-1013
Enrollment Status: Completed
Publish Date: March 27, 2017
Intervention Type: Biological
Study Phase: Phase 1
View 5 Less Clinical Trials

29 Total Publications

Results of the first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.
Results of the first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.
Journal: The journal of prevention of Alzheimer's disease
Published: March 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Yachnin's expertise for a condition
ConditionClose
        View All 10 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile